NovoCure (NVCR) Cash from Operations Growth (3y) (2017 - 2026)
NovoCure (NVCR) Cash from Operations Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.43 Bn | 193.83 Bn | 7.27 Bn | 27.41% |
| 2 | Stryker | 126.52 Bn | 123.04 Bn | 4.50 Bn | 22.38% |
| 3 | Medtronic | 118.76 Bn | 109.54 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | 30.85% |
| 5 | Edwards Lifesciences | 52.20 Bn | 47.95 Bn | 1.35 Bn | 168.71% |
| 6 | Dexcom | 34.51 Bn | 32.56 Bn | 830.00 Mn | 12.26% |
| 7 | GE HealthCare Technologies | 33.75 Bn | 31.65 Bn | 2.18 Bn | 65.19% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 43.79% |
| 9 | Steris | 23.09 Bn | 22.61 Bn | 684.20 Mn | 9.30% |
| 10 | NovoCure | 2.07 Bn | 1.63 Bn | 142.48 Mn | 33.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.09% |
| Mar 31, 2026 | 6.86% |
| Dec 31, 2025 | -69.35% |
| Sep 30, 2025 | -2.82% |
| Jun 30, 2025 | -44.40% |
| Mar 31, 2025 | -113.07% |
| Dec 31, 2024 | -30.83% |
| Sep 30, 2024 | -24.80% |
| Jun 30, 2024 | -27.36% |
| Mar 31, 2024 | -55.72% |
| Dec 31, 2023 | -31.47% |
| Sep 30, 2023 | -37.92% |
| Jun 30, 2023 | -55.84% |
| Mar 31, 2023 | -119.30% |
| Dec 31, 2022 | -36.31% |
| Sep 30, 2022 | 14.57% |
| Jun 30, 2022 | 20.24% |
| Mar 31, 2022 | 5.11% |
| Dec 31, 2021 | -5.03% |
| Sep 30, 2021 | 62.96% |